Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. (002550)

Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. (002550)

Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. is a leading production and operation enterprise of polysaccharides and protease drugs in the biochemical pharmaceutical industry in China. It is a national high-tech enterprise and key key enterprise of the national three drug bases. It has won the title of national, provincial and municipal pharmaceutical quality and integrity demonstration enterprise for many years. On February 18th, 2011, it was listed in Shenzhen Stock Exchange. At present, Jiangsu Zhonghong bioengineering and Pharmaceutical Research Institute Co., Ltd. (hereinafter referred to as "Zhonghong biology"), Changzhou inno Shengkang Biomedical Technology Co., Ltd. (hereinafter referred to as "yingnushengkang"), Jiangsu Jinghong Biomedical Technology Co., Ltd. (hereinafter referred to as "jinghongsheng family"), and Hubei Runhong Biotechnology Co., Ltd. (abbreviated as Hubei Runhong) four holding subsidiaries.

The main products of the company are the first in China, including the series of Kallidinogenase, heparin sodium and low molecular heparin, compound digestive enzyme preparation and asparaginase. The production technology and quality level have reached the international and domestic advanced level. Many products have passed the quality certification organized by the United States, the European Union and Japan. The company has established a perfect domestic and foreign marketing network system, products throughout more than 20 provinces and cities, and exported to European and American and Japanese international markets.

The company has established Changzhou Qianhong international biomedical innovation drug incubation base, has advanced R & D platform in the industry, and has made significant progress in the research of multiple gene recombinant protein drugs and targeted anti-tumor drugs, and has already entered human clinical trials with multiple first-class new drugs; At the same time, it also undertakes a number of major national and ministerial level science and technology research and development projects, which provides a strong core competitiveness for the development and growth of the company.

Looking forward to the future, the company will adhere to the development strategy of "focusing on the field of biomedicine, guiding core competitiveness with innovative drugs, and deeply cultivating the domestic pharmaceutical market and export of high-value-added varieties", and strive to become a first-class and competitive large-scale biomedical enterprise in China.

>>server parts deals for server parts picker Tungsten Rings for Men and Women boxing equipment for sale